Moderna is trading 4.3% down at $65.32 following news that Sanofi has filed new patent infringement lawsuits against the company in U.S. federal court.
- Sanofi alleges that Moderna’s COVID-19 vaccine utilizes lipid nanoparticle (LNP) technology covered by patents held through its Translate Bio unit.
- The litigation adds to a complex series of ongoing mRNA intellectual property disputes, heightening investor concerns regarding legal and royalty-related risks.
- The lawsuits were filed in New Jersey federal court, marking a significant escalation in the battle over foundational vaccine technology.